Literature DB >> 8239566

Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity.

S Przedborski1, V Jackson-Lewis, U Muthane, H Jiang, M Ferreira, A B Naini, S Fahn.   

Abstract

Parkinson's disease (PD) is characterized mainly by a loss of nigrostriatal dopamine neurons. Thus far, the actual physiopathology of PD remains uncertain, although recent studies have found decreased activity of complex I, one of the enzymatic units of the mitochondrial respiratory chain, in various tissues of PD patients. Because most, if not all, of PD patients are treated chronically with levodopa, the precursor of dopamine, and because we have shown previously that catecholamines may alter mitochondrial respiration, we assessed the effects of chronic administration of levodopa on complex I activity in rat brain. We found that chronic administration of levodopa, at a dose used in PD patients, caused a significant reduction in complex I activity while it did not affect the activities of complex II, complex IV, and citrate synthase. Reduction in complex I activity correlated well with catecholamine innervation as the reduction was observed mainly in the striatum and substantia nigra and to a lesser extent in the frontal cortex but not in the cerebellum. Moreover, the levodopa-induced decrease of complex I activity was reversible since activities at 1, 3, and 7 days after the last injection showed a progressive return to control values. Incubation of whole brain mitochondria in vitro showed that both levodopa and dopamine inhibit complex I activity in a dose- and time-dependent manner. In contrast, other compounds such as homovanillic acid, 3,4-dihydroxyphenylacetic acid, and 3-O-methyl-dopa were minimally effective. Reduced glutathione, ascorbate, superoxide dismutase, and catalase prevented the effect of levodopa and dopamine on complex I. Various inhibitors of monoamine oxidase also prevented the effect of dopamine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239566     DOI: 10.1002/ana.410340515

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  24 in total

Review 1.  Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.

Authors:  Rebecca Banerjee; Anatoly A Starkov; M Flint Beal; Bobby Thomas
Journal:  Biochim Biophys Acta       Date:  2008-11-14

Review 2.  Laboratory approach to mitochondrial diseases.

Authors:  D Parra; A González; C Mugueta; A Martínez; I Monreal
Journal:  J Physiol Biochem       Date:  2001-09       Impact factor: 4.158

Review 3.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

Review 4.  Mitochondrial dysfunction in neurodegeneration.

Authors:  J M Cooper; A H Schapira
Journal:  J Bioenerg Biomembr       Date:  1997-04       Impact factor: 2.945

5.  Cerebrospinal fluid lactate and pyruvate concentrations in patients with Parkinson's disease and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)

Authors:  M Yamamoto; H Ujike; K Wada; T Tsuji
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

Review 6.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

7.  Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics.

Authors:  I Maurer; H J Möller
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

Review 8.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

Review 9.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.